middle.news
Anteris Launches Global Trial for Innovative DurAVR Heart Valve
10:00am on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
Anteris Launches Global Trial for Innovative DurAVR Heart Valve
10:00am on Tuesday 28th of October, 2025 AEDT
Key Points
First patients treated in global PARADIGM Trial for DurAVR THV
Randomized controlled trial comparing DurAVR to existing TAVR devices
Approximately 1,000 patients to be enrolled across multiple countries
Trial aims to demonstrate safety and effectiveness for regulatory approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE